Expanding the Role for Immunotherapy in Triple-Negative Breast Cancer.
Journal
Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617
Informations de publication
Date de publication:
11 05 2020
11 05 2020
Historique:
entrez:
13
5
2020
pubmed:
13
5
2020
medline:
24
10
2020
Statut:
ppublish
Résumé
PD-1 axis blockade, in combination with chemotherapy, improves outcomes in advanced triple-negative breast cancer that is PD-L1 positive. The phase 3 KEYNOTE-522 trial now shows that the addition of pembrolizumab to chemotherapy improves pathological complete response rates regardless of PD-L1 status and appears to improve survival.
Identifiants
pubmed: 32396855
pii: S1535-6108(20)30206-3
doi: 10.1016/j.ccell.2020.04.007
pii:
doi:
Substances chimiques
130-nm albumin-bound paclitaxel
0
Albumins
0
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
B7-H1 Antigen
0
atezolizumab
52CMI0WC3Y
Paclitaxel
P88XT4IS4D
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
623-624Commentaires et corrections
Type : CommentOn
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Interests P.S. has served as an uncompensated consultant to Roche-Genentech. S.L. receives research funding to her institution from Novartis, Bristol Meyers Squibb, Merck, Roche-Genentech, Puma Biotechnology, Pfizer, Eli Lilly, and Seattle Genetics. She has acted as consultant (not compensated) to Seattle Genetics, Pfizer, Novartis, BMS, Merck, AstraZeneca, and Roche-Genentech. She has acted as consultant (paid to her institution) to Aduro Biotech, Novartis, and G1 Therapeutics.